Information  X 
Enter a valid email address

Summit Corporation PLC (SUMM)

  Print      Mail a friend

Tuesday 01 April, 2008

Summit Corporation PLC

Total voting rights

Summit Corporation plc
("Summit plc" or "the Company")

Oxford, UK, 2 April 2008 - Summit Corporation plc (AIM: SUMM)
notifies the market of the following information in order to conform
to 5.6.1 of the Disclosure and Transparency rules:

The issued share capital consists of 50,841,660 ordinary shares of
10p each with voting rights. No ordinary shares are held in treasury.

The above figure of 50,841,660 may be used by shareholders as the
denominator for the calculations by which they will determine if they
are required to notify their interest in, or a change to their
interest in the Company under the FSA's Disclosure and Transparency

                              - ENDS -

For more information, please contact:

Summit plc
Darren Millington, ACMA, Chief Financial Officer
Richard Pye, PhD, Investor Relations
Tel: +44 (0)1235 443951

Panmure Gordon
Andrew Burnett / Rakesh Sharma
Tel: +44 (0)207 459 3600

About Summit plc
Summit plc is a leading UK biotechnology company that discovers and
develops proprietary new drugs. The Company's internal drug
development programmes are underpinned by its advanced carbohydrate
chemistry and zebrafish drug screening technology platforms, which it
also provides on a collaborative or fee-for-service basis to the
pharmaceutical industry.
Summit plc has a broad range of drug discovery programmes in the
clinical, pre-clinical and discovery stages of development, which
target serious diseases with a high unmet medical need. These
therapeutic areas include neurological disorders, anti-infectives,
ophthalmic diseases and oncology.
Summit plc's in-house drug development capabilities combine
world-class expertise in both carbohydrate chemistry with
high-volume, high-content screening using its proprietary zebrafish
technologies. These whole organism screens have the potential to
dramatically decrease the time and cost of drug discovery and
development by delivering data that are highly predictive of the
efficacy and toxicity of potential drug compounds in humans.

The company listed on the AIM market of the London Stock Exchange in
October 2004 - symbol: SUMM

Further information about the company is available at